{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:04:20Z","timestamp":1792260260631,"version":"4.4.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jhep.2019.04.017","type":"journal-article","created":{"date-parts":[[2019,5,13]],"date-time":"2019-05-13T19:42:02Z","timestamp":1557776522000},"page":"473-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-8035","authenticated-orcid":false,"given":"Fanpu","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Tzuhen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Monica","family":"Preda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-3589","authenticated-orcid":false,"given":"Fabio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-892X","authenticated-orcid":false,"given":"Tatsuya","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-2016","authenticated-orcid":false,"given":"Rob","family":"Bielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Sezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-5127","authenticated-orcid":false,"given":"Michele","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0702-2101","authenticated-orcid":false,"given":"Philippe","family":"Kolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-2760","authenticated-orcid":false,"given":"Po-sung","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6282-0755","authenticated-orcid":false,"given":"Victor","family":"Virlogeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Eurich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2353-4227","authenticated-orcid":false,"given":"Michelle B.","family":"Bass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangsuo","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-1418","authenticated-orcid":false,"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0222-2251","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.04.017_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","article-title":"Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma","volume":"67","author":"Cabibbo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/apt.13034","article-title":"Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study","volume":"41","author":"Chong","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1478-3231.2011.02634.x","article-title":"Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma","volume":"32","author":"Chan","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0025","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1111\/liv.12805","article-title":"A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib","volume":"35","author":"Yang","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/apt.14801","article-title":"Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience","volume":"48","author":"Chen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jhep.2017.02.027","article-title":"Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma","volume":"67","author":"Beste","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0045","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","article-title":"Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals","volume":"66","author":"Prenner","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0050","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.29126","article-title":"Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma","volume":"66","author":"Saberi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0055","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/apt.14685","article-title":"High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma","volume":"47","author":"Persico","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2019.04.017_b0060","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006128","article-title":"Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease","volume":"96","author":"Chang","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2019.04.017_b0065","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/apt.14507","article-title":"Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia","volume":"47","author":"Ji","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0070","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.29701","article-title":"Hepatocellular carcinoma decreases the effectiveness of hepatitis C antiviral treatment: do direct-acting antiviral regimens matter?","volume":"67","author":"Ji","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0075","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2019.04.017_b0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2019.04.017_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jhep.2019.04.017_b0090","unstructured":"Wells GA, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed June 1, 2018."},{"key":"10.1016\/j.jhep.2019.04.017_b0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Health"},{"key":"10.1016\/j.jhep.2019.04.017_b0100","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2019.04.017_b0105","first-page":"40","article-title":"Meta: an R package for meta-analysis","volume":"7","author":"Schwarzer","year":"2007","journal-title":"R News"},{"key":"10.1016\/j.jhep.2019.04.017_b0110","series-title":"ggplot2: elegant graphics for data analysis","author":"Hadley","year":"2009"},{"key":"10.1016\/j.jhep.2019.04.017_b0115","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/liv.13384","article-title":"The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings","volume":"37","author":"Sezaki","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0120","doi-asserted-by":"crossref","first-page":"E120","DOI":"10.1111\/hepr.12738","article-title":"Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis","volume":"47","author":"Ogawa","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2019.04.017_b0125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/jvh.12665","volume":"24","author":"Toyoda","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.04.017_b0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","article-title":"Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan","volume":"53","author":"Suda","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"Iio","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179096","article-title":"On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C","volume":"12","author":"Chu","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.04.017_b0145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.5604\/01.3001.0010.2732","article-title":"Outcomes for cirrhotic patients with hepatitis C virus 1b treated with asunaprevir and daclatasvir combination","volume":"16","author":"Tamori","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0150","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/hepr.12673","article-title":"Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir\/asunaprevir therapy by a two-hit mechanism","volume":"46","author":"Uchida","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2019.04.017_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163884","article-title":"Evaluation of resistance-associated substitutions in NS5A using direct sequence and cycleave method and treatment outcome with daclatasvir and asunaprevir for chronic hepatitis C genotype 1","volume":"11","author":"Ide","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jhep.2019.04.017_b0160","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1159\/000448822","article-title":"Outcome of asunaprevir\/daclatasvir combination therapy for chronic liver disease type C","volume":"34","author":"Hagiwara","year":"2016","journal-title":"Dig Dis"},{"key":"10.1016\/j.jhep.2019.04.017_b0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2017.05.028","article-title":"Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C","volume":"67","author":"Nagata","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0170","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2016.07.043","article-title":"The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma","volume":"65","author":"Minami","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0175","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","article-title":"NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b","volume":"52","author":"Ogawa","year":"2017","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0180","doi-asserted-by":"crossref","first-page":"E906","DOI":"10.3390\/ijms18050906","volume":"18","author":"Kanda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2019.04.017_b0185","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/hepr.12898","article-title":"Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy","volume":"47","author":"Iio","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2019.04.017_b0190","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00535-018-1455-1","article-title":"Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group","volume":"53","author":"Tsuji","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2016.10.012","article-title":"Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis","volume":"136","author":"Ogawa","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2019.04.017_b0200","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3748\/wjg.v24.i13.1478","article-title":"Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir\/ribavirin for Japanese genotype 2 hepatitis C virus","volume":"24","author":"Yada","year":"2018","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0205","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/apt.13541","article-title":"Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment experienced cirrhotic genotype 1b patients with HCV","volume":"43","author":"Zeng","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0210","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1038\/s41598-018-32060-7","article-title":"Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2019.04.017_b0215","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.017_b0220","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ajg.2015.422","article-title":"Simeprevir and sofosbuvir (SMV-SOF) for 12 weeks for the treatment of chronic hepatitis C genotype 1 infection: a real world (transplant) hepatology practice experience","volume":"111","author":"Pillai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0225","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0230","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jvh.12663","article-title":"Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older","volume":"24","author":"Conti","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.04.017_b0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jvh.12765","article-title":"A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study","volume":"25","author":"Barone","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.04.017_b0240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2016.08.016","article-title":"Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?","volume":"66","author":"Zavaglia","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0245","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0250","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MEG.0000000000001082","article-title":"Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study","volume":"30","author":"Adhoute","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0260","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","author":"ANRS collaborative study group on hepatocellular carcinoma","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0265","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12647","article-title":"Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir\/ledipasvir: the role of ribavirin","volume":"19","author":"Globke","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2019.04.017_b0270","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0275","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/lt.24790","article-title":"Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus\u2013infected patients treated with direct-acting antivirals","volume":"23","author":"Zanetto","year":"2017","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2019.04.017_b0280","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0285","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0290","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3851\/IMP3168","article-title":"Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir\u202f\u00b1\u202fribavirin for hepatitis C genotype 1 \u2013 final results of the REV1TAL study","volume":"22","author":"Lubel","year":"2017","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2019.04.017_b0295","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.drugalcdep.2017.04.003","article-title":"Belgian experience with direct acting antivirals in people who inject drugs","volume":"177","author":"Bielen","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jhep.2019.04.017_b0300","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/liv.13550","article-title":"Real-world efficacy and safety of ombitasvir, paritaprevir\/r\u202f+\u202fdasabuvir\u202f+\u202fribavirin in genotype 1b patients with hepatitis C virus cirrhosis","volume":"38","author":"Preda","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0305","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jhep.2017.07.007","article-title":"Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a European multicentre study","volume":"67","author":"Kolly","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0310","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/liv.13266","article-title":"Real life Egyptian experience of efficacy and safety of simeprevir\/sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients","volume":"37","author":"Eletreby","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.017_b0315","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jvh.12854","article-title":"Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: a comparative analysis","volume":"25","author":"El Kassas","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.04.017_b0320","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0000000000001152","article-title":"Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact","volume":"30","author":"Hassany","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.5604\/01.3001.0011.7388","article-title":"Sofosbuvir-based therapy in the pre-liver transplant setting: The Canadian national experience","volume":"17","author":"Al-Judaibi","year":"2018","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0330","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5114\/ceh.2017.71483","article-title":"Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment-Preliminary report","volume":"3","author":"Warzyszy\u0144ska","year":"2017","journal-title":"Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0335","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOG.0000000000000431","article-title":"Direct-acting antiviral treatment for patients with hepatocellular carcinoma","volume":"34","author":"Kushner","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.017_b0340","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/hep.29556","article-title":"OATP1B1 and DAA treatment for hepatitis C in patients with hepatocellular carcinoma","volume":"66","author":"Chtioui","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0345","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2017.06.037","article-title":"Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma","volume":"68","author":"Fangazio","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0350","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/hep.29181","article-title":"Unexpected viral relapses in hepatitis C virus-infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals","volume":"66","author":"Soria","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0355","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.4254\/wjh.v7.i17.2080","article-title":"Immunology of hepatocellular carcinoma","volume":"7","author":"Sachdeva","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0360","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.28926","article-title":"Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list","volume":"65","author":"Chhatwal","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.017_b0365","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jvh.12877","article-title":"The optimal timing of hepatitis C therapy in liver transplant-eligible patients: cost-effectiveness analysis of new opportunities","volume":"25","author":"Cortesi","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2019.04.017_b0370","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1111\/ajt.14965","article-title":"Very late relapse of hepatitis C virus infection immediately after liver transplantation","volume":"18","author":"Erard-Poinsot","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2019.04.017_b0375","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.gastro.2016.07.038","article-title":"Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial","volume":"151","author":"Gane","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.017_b0380","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2017.11.032","article-title":"Resistance analysis in patients with genotype 1\u20136 HCV infection treated with sofosbuvir\/velpatasvir in the phase III studies","volume":"68","author":"Hezode","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0385","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0390","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir: integrated analysis of HCV genotype 1\u20136 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.017_b0395","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S2468-1253(17)30163-2","volume":"2","author":"Lawitz","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2019.04.017_b0400","doi-asserted-by":"crossref","first-page":"A332","DOI":"10.1289\/ehp.1103768","article-title":"Three criteria for ecological fallacy","volume":"119","author":"Idrovo","year":"2011","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.jhep.2019.04.017_b0405","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12272","article-title":"JSH guidelines for the management of hepatitis C virus infection: a 2014 update for genotype 1","volume":"441","author":"Drafting Committee for Hepatitis Management Guidelines","year":"2014","journal-title":"Hepatol Res"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781930279X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781930279X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T12:18:18Z","timestamp":1607775498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781930279X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S016882781930279X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.04.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.04.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}